{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:13:41Z","timestamp":1791486821186,"version":"4.3.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015438","name":"International Society on Thrombosis and Haemostasis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtha.2024.02.011","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T03:40:04Z","timestamp":1710733204000},"page":"1779-1797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-9043","authenticated-orcid":false,"given":"Sam","family":"Schulman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Broxmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kaatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Minichiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ramacciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helaine E.","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Marc","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zarychanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.02.011_bib1","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"10.1016\/j.jtha.2024.02.011_bib3","series-title":"Tracking coronavirus vaccinations around the world","author":"Holder","year":"2023"},{"key":"10.1016\/j.jtha.2024.02.011_bib4","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"Schulman","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIR.0b013e31827e8e5f","article-title":"ACCF\/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"Jacobs","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.02.011_bib8","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"American Heart Association\/American Stroke Association. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.02.011_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.02.011_bib11","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1093\/cid\/ciab813","article-title":"Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019","volume":"75","author":"Ananworanich","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtha.2024.02.011_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102004","article-title":"Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial","volume":"60","author":"Avezum","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jtha.2024.02.011_bib13","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.123.063901","article-title":"Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial","volume":"147","author":"Piazza","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.02.011_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/a-1414-5216","article-title":"Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial","volume":"121","author":"Gonzalez-Ochoa","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib15","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(22)00175-2","article-title":"Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"9","author":"Barco","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.02.011_bib16","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2352-3026(22)00173-9","article-title":"Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial","volume":"9","author":"Cools","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.02.011_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2459\/JCM.0000000000001284","article-title":"Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes","volume":"23","author":"Battistoni","year":"2022","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jtha.2024.02.011_bib18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1055\/a-1366-9656","article-title":"Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients","volume":"121","author":"Cohen","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1055\/a-1347-6070","article-title":"Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study","volume":"121","author":"Di Castelnuovo","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/ejh.13533","article-title":"Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis","volume":"106","author":"Ionescu","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2024.02.011_bib21","doi-asserted-by":"crossref","first-page":"n311","DOI":"10.1136\/bmj.n311","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.02.011_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10557-020-07133-3","article-title":"The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19","volume":"36","author":"Shen","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jtha.2024.02.011_bib23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11739-021-02891-w","article-title":"Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register","volume":"17","author":"Poli","year":"2022","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib24","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.02.011_bib25","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12638","article-title":"RAPID Trial Investigators. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis","volume":"5","author":"Sholzberg","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12712","article-title":"Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: the Swiss COVID-HEP randomized clinical trial","volume":"6","author":"Blondon","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib29","first-page":"5632","article-title":"Efficacy and safety of tinzaparin in prophylactic, intermediate and therapeutic doses in non-critically ill patients hospitalized with COVID-19: the PROTHROMCOVID randomized controlled trial","volume":"11","author":"Mu\u00f1oz-Rivas","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2023.02.041","article-title":"Randomized trial of anticoagulation strategies for noncritically ill patients hospitalized with COVID-19","volume":"81","author":"Stone","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2024.02.011_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00408-023-00599-6","article-title":"full anticoagulation. The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically ill COVID-19 patients: a meta-analysis of high quality studies","volume":"201","author":"Pilia","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.jtha.2024.02.011_bib32","article-title":"Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 randomized trial","author":"Morici","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jtha.2024.02.011_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102031","volume":"60","author":"Zuily","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jtha.2024.02.011_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.02.011_bib35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.02.011_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S2213-2600(22)00298-3","article-title":"Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial","volume":"10","author":"Eikelboom","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib37","first-page":"11","article-title":"Oral rivaroxaban in the prophylaxis of COVID-19 induced coagulopathy","volume":"70","author":"Kumar","year":"2022","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1016\/j.jtha.2024.02.011_bib38","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1002\/jmv.26918","article-title":"Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry","volume":"93","author":"Kirkup","year":"2021","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jtha.2024.02.011_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jama.2023.3651","article-title":"Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19","volume":"329","author":"Goligher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.02.011_bib41","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jtha.2023.04.045","article-title":"A\u00a0randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial","volume":"21","author":"Kanagaratnam","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib42","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1111\/jth.15809","article-title":"Good practice statements for antithrombotic therapy in the management of COVID-19","volume":"20","author":"Spyropoulos","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib43","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial","volume":"19","author":"Perepu","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib44","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"INSPIRATION Investigators","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.02.011_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamainternmed.2023.0456","article-title":"Effects of standard-dose prophylactic, high-dose prophylactic, and therapeutic anticoagulation in patients with hypoxemic COVID-19 pneumonia: the ANTICOVID randomized clinical trial","volume":"183","author":"Labb\u00e9","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib46","first-page":"1032","article-title":"Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of COVID-19-associated coagulopathy","volume":"11","author":"Oliynyk","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jtha.2024.02.011_bib47","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1161\/CIRCULATIONAHA.122.061533","article-title":"Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically ill patients with COVID-19: COVID-PACT","volume":"146","author":"Bohula","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.02.011_bib48","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"327","author":"Bradbury","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.02.011_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14428","article-title":"Effect of P2Y12 inhibitors on organ support-free survival in critically ill patients hospitalized for COVID-19: a randomized clinical trial","volume":"6","author":"Berger","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.02.011_bib50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2022.23257","article-title":"Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial","volume":"329","author":"Higgins","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.02.011_bib51","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00134-023-07095-8","article-title":"Continuation of therapeutic dose heparin for critically ill patients with COVID-19","volume":"49","author":"Bradbury","year":"2023","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100185","article-title":"The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin","volume":"7","author":"Sytema","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib54","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/M22-3350","article-title":"Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization","volume":"176","author":"Wang","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib55","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood.2020010529","article-title":"Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry","volume":"137","author":"Giannis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.02.011_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.02.011_bib57","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/10600280211064306","article-title":"Evaluation of the clinical impact of thromboprophylaxis in patients with COVID-19 following hospital discharge","volume":"56","author":"Courtney","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2024.02.011_bib58","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35397","article-title":"Factors associated with risk of postdischarge thrombosis in patients with COVID-19","volume":"4","author":"Li","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.02.011_bib59","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/bjh.18874","article-title":"Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with COVID-19: multicentre observational study in the UK","volume":"202","author":"Arachchillage","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.02.011_bib60","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1055\/s-0037-1603929","article-title":"The IMPROVEDD VTE risk score: incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification","volume":"1","author":"Gibson","year":"2017","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2024.02.011_bib61","doi-asserted-by":"crossref","first-page":"142","DOI":"10.12688\/wellcomeopenres.17735.1","article-title":"Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform","volume":"7","author":"Tazare","year":"2022","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jtha.2024.02.011_bib62","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.26848","article-title":"Venous thromboembolism after COVID-19 vaccination in patients with thrombophilia","volume":"98","author":"Houghton","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.02.011_bib63","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2022007766","article-title":"The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Bissola","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.02.011_bib64","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: a multicenter study comprising 1284 patients","volume":"20","author":"Favaloro","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib65","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1016\/j.vaccine.2022.06.014","article-title":"Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: description of a series of 39 cases in Brazil","volume":"40","author":"Mouta Nunes de Oliveira","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jtha.2024.02.011_bib66","article-title":"Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany","volume":"12","author":"Thiele","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtha.2024.02.011_bib67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/a-1986-1556","article-title":"Diagnostic performance of a particle gel immunoassay in vaccine-induced immune thrombotic thrombocytopenia","volume":"43","author":"Uzun","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.02.011_bib68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2022.03.034","article-title":"Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis","volume":"119","author":"Kim","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jtha.2024.02.011_bib69","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.02.011_bib70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","article-title":"Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study","volume":"398","author":"Perry","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.02.011_bib71","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ana.26431","article-title":"Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination","volume":"92","author":"Scutelnic","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jtha.2024.02.011_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102243","article-title":"Vaccine-induced immune thrombotic thrombocytopenia post COVID-19 booster vaccination in Brazil: a case series","volume":"7","author":"Mendes-de-Almeida","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib73","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/jth.15491","article-title":"Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"19","author":"Khan","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.02.011_bib74","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2024.02.011_bib75","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/bloodadvances.2021006698","article-title":"A\u00a0novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Lee","year":"2022","journal-title":"Blood Adv"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T19:47:26Z","timestamp":1718826446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1538783624001132"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}